New Small Molecules That Boost the Heart-Protective Effects of Natriuretic Peptides ANP and BNP

High-throughput screening and in silico design identified novel small molecule allosteric enhancers of GC-A. These compounds enhanced ANP and BNP effects in cellular systems expressing GC-A and enhanced ANP-induced vasorelaxation in rat aortic rings. The mechanism is novel — not mediated through previously known allosteric binding sites. Selectivity between GC-A and the related receptor GC-B depended on a single amino acid residue. The compounds represent a new class of tools for enhancing natriuretic peptide signaling.

High-throughput screening identified initial hits, which were optimized through in silico computational design. GC-A activation was measured via cyclic GMP production in QBIHEK293A cells expressing GC-A, GC-B, or chimeric receptors using AlphaScreen technology. Binding assays used 125I-ANP in membrane preparations and whole cells. Functional vasorelaxation was tested in isolated Wistar rat aortic rings. Receptor selectivity was mapped to individual amino acid residues using chimeric GC-A/GC-B receptors.

Heart failure treatment has long sought a way to boost the natriuretic peptide system without injecting peptides. These small molecules could become the first oral drugs that enhance the body's own cardiac protection. By amplifying rather than replacing natriuretic peptide signaling, they work with the body's natural regulatory system — potentially avoiding the hypotension issues that limited nesiritide's clinical success.

The natriuretic peptide system is one of the body's most important cardiovascular protective mechanisms, but pharmaceutical exploitation has been limited to injectable peptides. Small molecule allosteric enhancers represent a breakthrough approach — they could make oral GC-A-targeted therapy possible for the first time. This concept of 'enhancing endogenous peptide signaling' rather than replacing it with exogenous peptides is a paradigm that could extend to other peptide receptor systems across medicine.

All experiments were in vitro and in isolated rat tissue — no in vivo cardiovascular effects were tested. The pharmacokinetic properties (oral bioavailability, half-life, metabolism) of the compounds are unknown. The compounds enhance peptide effects rather than activating GC-A independently, meaning they depend on adequate endogenous ANP/BNP levels. Whether the vasorelaxation effect translates to blood pressure reduction in living animals is untested. The selectivity mechanism (single amino acid) may complicate drug development if species differences exist.